In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Twin Acquisitions, China-wide Plasma Shortage, Boost Earnings For China Biologic

This article was originally published in PharmAsia News

Executive Summary

BEIJING - The leadership of China Biologic Products, the country's biggest privately held provider of plasma-based biopharmaceuticals, said that the acquisition of two competitors earlier this year helped elevate profits in the second quarter, and that the emergence of the A/H1N1 pandemic could bolster sales throughout the year

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts